Double-blind placebo controlled trial of tibolone and oestrogen hormone therapy on oxidative stress associated to postmenopausal disturbances in women with early postmenopause: MOS study
| ISRCTN | ISRCTN14939779 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14939779 |
| Protocol serial number | N/A |
| Sponsor | National Autonomous University of Mexico |
| Funder | National Autonomous University of Mexico |
- Submission date
- 08/09/2017
- Registration date
- 19/09/2017
- Last edited
- 11/10/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Menopause is an expected event in a woman’s life due to ovarian aging. Ovarian aging is produced by a series of hormonal changes that leads to the erratic production of estrogens that eventually leads to low estrogen levels (menopause). Menopause is associated with multiple symptoms that affects self-esteem and quality of life of the women. The marked reduction in estrogens has been shown to increase levels of oxidative stress (OS) in the body. Oxidative stress is an imbalance between the production of free radicals and the body’s ability to neutralize them by antioxidans. Therefore menopause is a risk factor for OS, which may be due to an estrogenic deficiency and severity of symptoms. Hormone therapy (HT) with estrogen with or without progestin (synthetic progestogens), is a therapeutic alternative for women seeking help to ease their symptoms that occur after menopause, also with antioxidant effect. However, this type of therapy is controversial and can have negative short-term and long-term effects, even leading to treatment withdrawal. An alternative to HT has been the use of tibolone, a molecule with selective activity as estrogen, progestin and androgen, that has effect over postmenopausal symptoms and has not shown side effects, but it has not been clear whether it is an antioxidant molecule. The aim of this study is to determine the effect of tibolone on OS associated with mood disorders, climacteric symptoms, loss of muscle function and bone mineral density, that modify self-esteem and quality of life in postmenopausal women, compared with HT and placebo.
Who can participate?
Women aged 45-59 who have not had menstruation in 12 months.
What does the study involve?
Participants are randomly allocated to one of three groups. Those in the first group receive 2.5 mg/d of tibolone daily for 18 months. Those in the second group receive 0.625 mg/g of synthetic conjugated estrogen as well as 5 mg/10 g of medroxyprogesterone. Those in the last group receive a placebo (a dummy medication). Participants are followed up at six months to measure their oxidative stress and other symptoms.
What are the possible benefits and risks of participating?
The treatment may improve participant’s women postmenopausal symptoms and quality of life. There are no risks to the health for participants with hormone treatment or placebo.
Where is the study run from?
National Autonomous University of Mexico (Mexico)
When is the study starting and how long is it expected to run for?
November 2016 to April 2020 (updated 10/07/2020, previously: July 2019)
Who is funding the study?
National Autonomous University of Mexico (Mexico)
Who is the main contact?
Dr Martha A. Sanchez-Rodriguez
masanrod@yahoo.com.mx
Contact information
Scientific
Av. Guelatao No. 66 Col
Ejercito de Oriente
Mexico City
09230
Mexico
 ORCID ID |
0000-0002-7130-4074 |
|---|---|
| Phone | +52 15556230750 |
| masanrod@yahoo.com.mx |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective randomized double-blind trial single-centre |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Menopause and Oxidative Stress Study (MOS): Effects of tibolone and oestrogen hormone therapy on oxidative stress associated to mood disturbances, insomnia, loss of muscle function and bone mineral density, that affect self-esteem and quality of life in postmenopausal women |
| Study acronym | MOS |
| Study objectives | Considering that tibolone improves the symptoms present in postmenopausal period, and has a possible antioxidant activity, we assume that women with tibolone therapy will have a decrease in oxidative stress associated with postmenopausal disturbances, improving their quality of life and self-esteem, as well as those taking oestrogen therapy, and with an opposite effect to women receiving placebo. |
| Ethics approval(s) | Ethics Committee of the Universidad Nacional Autonoma de Mexico, 12/01/2017, ref: FESZ/DEPI/CI/004/17; |
| Health condition(s) or problem(s) studied | Postmenopausal women with or without mood disturbances, insomnia, loss of muscle function and bone mineral density, that affect self-esteem and quality of life. |
| Intervention | The treatment allocation is done using the simple random method with a scientific calculator. Three groups are formed: 1. Women with 2.5 mg/d of tibolone 2. Women with 0.625 mg/d of synthetic conjugated oestrogens + 5 mg/10 d of medroxyprogesterone 3. Women taking placebo (pharmaceutical presentation similar to the treatment) All the treatments are taken by oral administration. The therapy follow up will be during 18 months with assessments at baseline and ever 6 months. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | tibolone |
| Primary outcome measure(s) |
Oxidative stress is measured using lipoperoxide levels by TBARS assay, erythrocyte superoxide dismutase (SOD), erythrocyte glutathione peroxidase (GPx), total plasma antioxidant status and uric acid, using Randox Laboratories kits, at baseline measurement prior to initiation of therapy, and every 3 months. |
| Key secondary outcome measure(s) |
1. Hot flashes is measured using women's self-report diaries regarding how many total hot flashes they had per day during a week as well as information regarding the severity of each of these hot flashes (mild, moderate, severe, or very severe). The diaries are picked up at baseline and every 3 months. |
| Completion date | 30/04/2020 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target sample size at registration | 150 |
| Key inclusion criteria | 1. Women aged 45-59 with intact uterus 2. At least 12 months of spontaneous amenorrhea and/or serum estradiol levels less 25 pg/mL and follicle stimulating hormone (FSH) levels higher 50 mU/mL |
| Key exclusion criteria | 1. Women with cardiovascular, renal, hepatic or cancer disease 2. Antioxidant supplement intake for at least six months prior to the beginning of the study 2. Previous hormone therapy 3. Those who do not agree to participate in the study |
| Date of first enrolment | 02/10/2017 |
| Date of final enrolment | 01/04/2020 |
Locations
Countries of recruitment
- Mexico
Study participating centre
Guelatao # 66
Mexico City
09230
Mexico
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request from Dr. Martha A. Sanchez-Rodriguez, e-mail: masanrod@yahoo.com.mx or request a copy in the institutional website: http://condor.zaragoza.unam.mx/fesz_website_2011/?page_id=4004. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Other publications | Oxidative Stress Risk Is Increased with a Sedentary Lifestyle during Aging in Mexican Women | 25/10/2021 | 11/10/2023 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
11/10/2023: Publication reference added.
10/07/2020: The following changes were made to the trial record:
1. The recruitment end date was changed from 15/12/2017 to 01/04/2020.
2. The overall end date was changed from 30/07/2019 to 30/04/2020.
3. The intention to publish date was changed from 15/10/2019 to 30/04/2021.
4. The plain English summary was updated to reflect these changes.
